Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) Net Margin (2023 - 2025)

CG Oncology filings provide 3 years of Net Margin readings, the most recent being 1776.74% for Q4 2025.

  • On a quarterly basis, Net Margin rose 519650.0% to 1776.74% in Q4 2025 year-over-year; TTM through Dec 2025 was 3981.26%, a 374806.0% increase, with the full-year FY2025 number at 3985.02%, up 374447.0% from a year prior.
  • Net Margin hit 1776.74% in Q4 2025 for CG Oncology, up from 2623.53% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 1776.74% in Q4 2025 to a low of 2249000.0% in Q4 2023.
  • Median Net Margin over the past 3 years was 12001.04% (2024), compared with a mean of 259531.23%.
  • Biggest five-year swings in Net Margin: skyrocketed 224202675bps in 2024 and later tumbled -6306271bps in 2025.
  • CG Oncology's Net Margin stood at 2249000.0% in 2023, then skyrocketed by 100bps to 6973.25% in 2024, then soared by 75bps to 1776.74% in 2025.
  • The last three reported values for Net Margin were 1776.74% (Q4 2025), 2623.53% (Q3 2025), and 66263.46% (Q1 2025) per Business Quant data.